Evaluation of calcimimetic therapy in hemodialysis patients with secondary hyperparathyroidism: a real-world observational study

Evaluation of calcimimetic therapy in hemodialysis patients with secondary hyperparathyroidism: a real-world observational study - ETERNAL Study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000030354

Enrollment

3000

Registered

2017-12-11

Start date

2017-12-11

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hemodialysis patients with secondary hyperparathyroidism

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Patients 20 years of age or older at the time of consent 2) Patients able to provide written consent themselves 3) Hemodialysis patients with secondary hyperparathyroidism who satisfy the following 3 conditions: (1) Patients with an iPTH value of 300 pg/mL or above (wPTH of 177 pg/mL or above) (2) Patients with a corrected calcium concentration of 9.0 mg/dL or above (ionized calcium of 2.25 mEq/L or above) (3) Patients being treated with an active vitamin D preparation alone, cinacalcet alone, or a combination of both

Exclusion criteria

Exclusion criteria: 1) Patients with history of hemodialysis for less than 3 months at the time of eligibility confirmation 2) Patients who are inpatients at the time of eligibility confirmation 3) Patients who are planned to undergo surgery or be admitted to hospital at the time of eligibility confirmation where this will affect evaluation 4) Patients determined to be unsuitable for registration by the lead principal investigator or subinvestigator

Design outcomes

Primary

Measure	Time frame
Combined end-point of all deaths and hospitalization due to cardiovascular events	—

Countries

Japan

Contacts

Public ContactKoichi Kigawa

Mebix Inc. Data Science Division

eternal-study@mebix.co.jp03-6860-2528

Outcome results